Home > Oncology > ASCO 2020 > Advanced breast cancer: locoregional therapy does not improve OS

Advanced breast cancer: locoregional therapy does not improve OS

Results from the long-awaited E2108 trial showed that, in patients with metastatic breast cancer, local therapy did not improve overall survival (OS) when compared with optimal systemic therapy alone. The addition of locoregional therapy also failed to improve 3-year progression-free survival (PFS). However, recurrence or progression was significantly higher in the systemic arm alone.

With a median follow-up of 59 months, Prof. Seema Ahsan Khan (Feinberg School of Medicine, USA) presented the final follow-up data [1]. There has been a paucity of data about whether surgery and radiation to a breast tumour (local therapy) can prolong OS compared with systemic treatment alone. The goal of E2108 was to determine whether surgery and radiation should become routine practice for patients with stage IV breast cancer.

In total, 390 women with stage IV breast cancer were enrolled and received the o...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on